CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan-Induced Liver Toxicity

被引：13
|
作者：
Roustit, M. [1 ,2 ]
Fonrose, X. [3 ]
Montani, D. [4 ,5 ]
Girerd, B. [4 ,5 ]
Stanke-Labesque, F. [2 ,3 ]
Gonnet, N. [2 ]
Humbert, M. [4 ,5 ]
Cracowski, J-L [1 ,2 ]
机构：
[1] Univ Grenoble Alpes, INSERM UMR HP2 1042, Grenoble, France
[2] Grenoble Univ Hosp, Clin Pharmacol Unit, INSERM CIC1406, Grenoble, France
[3] Grenoble Univ Hosp, Lab Pharmacol, Grenoble, France
[4] Univ Paris Sud, AP HP, Ctr Natl Reference Hypertens Pulm Severe,DHU, Thorax Innovat TORINO,Hop Bicetre,Serv Pneumol, F-94275 Le Kremlin Bicetre, France
[5] Ctr Chirurg Marie Lannelongue, LabEx LERMIT, INSERM UMRS 999, Le Plessis Robinson, France
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 06期
关键词：
MECHANISM; INHIBITION; EXPORT;
D O I：
10.1038/clpt.2014.42
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Bosentan is an endothelin receptor antagonist used as a first-line treatment in pulmonary arterial hypertension (PAH). Its main adverse effect is a dose-dependent liver toxicity. CYP2C9*2 has recently been shown to be associated with hepatotoxicity in PAH patients. We conducted a nested case-control study to further explore the relationship between functional polymorphisms of gene products involved in bosentan pharmacokinetics (OATP1B1, OATP1B3, and CYP2C9) or hepatobiliary transporters affected by bosentan (ABCB11) and bosentan-induced liver toxicity.
引用
收藏
页码：583 / 585
页数：3
相关论文
共 50 条
  • [41] The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis
    Xiang, Qian
    Zhang, Xiaodan
    Ma, Lingyue
    Hu, Kun
    Zhang, Zhuo
    Mu, Guangyan
    Xie, Qiufen
    Chen, Shuqing
    Cui, Yimin
    PHARMACOGENETICS AND GENOMICS, 2018, 28 (12): : 261 - 267
  • [42] ABCG2 and SLCO1B1 gene polymorphisms in the Croatian population
    Bozina, Tamara
    Ganoci, Lana
    Karacic, Ena
    Simicevic, Livija
    Vrkic-Kirhmajer, Majda
    Klarica-Domjanovic, Iva
    Kriz, Tena
    Sertic, Zrinka
    Bozina, Nada
    ANNALS OF HUMAN BIOLOGY, 2022, 49 (7-8) : 323 - 331
  • [43] THE INFLUENCE OF SLCO1B3 POLYMORPHISMS ON DOCETAXEL DISPOSITION IN ASIAN NASOPHARYNGEAL CARCINOMA PATIENTS
    Chew, S.
    Mann, O.
    Ramasamy, R.
    Lim, W.
    Tan, E.
    Lee, E. J.
    Chowbay, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 52 - 52
  • [44] Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury
    Jin, Shasha
    Li, Xuesong
    Fan, Yujuan
    Fan, Xiaofang
    Dai, Yu
    Lin, Haishu
    Cai, Weimin
    Yang, Jialin
    Xiang, Xiaoqiang
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 (06) : 508 - 517
  • [45] The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition
    Jiang, Fen
    Choi, Jong-Yeol
    Lee, Ju-Hyun
    Ryu, Sunae
    Park, Ze-Won
    Lee, Jong-Gu
    Na, Han-Sung
    Lee, Seok-Yong
    Oh, Woo-Yong
    Chung, Myeon-Woo
    Choi, Seung-Eun
    PHARMACOGENOMICS, 2017, 18 (05) : 459 - 469
  • [46] ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population
    Tounsi, Nejia
    Trabelsi, Imen
    Kerkeni, Emna
    Grissa, Mohamed Habib
    Fredj, Nizar
    Sekma, Adel
    Mzali, Malek
    Hellara, Ilhem
    Monastiri, Kamel
    Douki, Wahiba
    Nouira, Semir
    PHARMACOLOGY, 2017, 99 (5-6) : 250 - 258
  • [47] Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin
    Niemi, Mikko
    Kivistoe, Kari T.
    Diczfalusy, Ulf
    Bodin, Karl
    Bertilsson, Leif
    Fromm, Martin F.
    Eichelbaum, Michel
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (08): : 565 - 568
  • [48] Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
    Aquilante C.L.
    Bushman L.R.
    Knutsen S.D.
    Burt L.E.
    Rome L.C.
    Kosmiski L.A.
    Human Genomics, 3 (1) : 7 - 16
  • [49] Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis
    Zhang, Zi Hao
    Sun, Li Chao Yue
    Gu, Hong Yan
    Jiang, De Chun
    Yi, Zhan Miao
    PHARMACOGENOMICS, 2023, 24 (08) : 475 - 484
  • [50] Polymorphisms of SLCO1B1 Gene in Sundanese Ethnic Population of Tuberculosis Patients in Indonesia
    Santoso, Prayudi
    Juliastuti, Henny
    Nataprawira, Heda Melinda
    Soeroto, Arto Yuwono
    Alisjahbana, Bachti
    Ruslami, Rovina
    Debora, Josephine
    Sribudiani, Yunia
    Maskoen, Ani Melani
    ACTA MEDICA INDONESIANA, 2022, 54 (04) : 517 - 523
12345